Results 181 to 190 of about 139,314 (301)

Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1. [PDF]

Commun Chem
Pandey P, Zagzoog AH, Zaharia T, Chatterjee S, Khan IA, Paris JJ, Laprairie RB, Chittiboyina AG.   +7 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors. [PDF]

Mol Pharmacol
Benton AJ, Johns MR, Diamant E, Rouzbeh N, Sørensen VP, Anderson CM, Secci D, Zhang Z, Rau AR, Clausen RP, Hansen KB.   +10 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

Epilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee, Peimin Yu, Eunyeong Choe, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Zhen Hong, Koji Iida, Yong Heui Jeon, Jiwon Jung, Marc Kamin, Kensuke Kawai, Ji Hyun Kim, Myung Won Kim, Xiaorong Liu, Jungshin Park, William Rosenfeld, Takamichi Yamamoto, Dong Zhou, Suiqiang Zhu, Sunita N. Misra   +20 more
wiley   +1 more source

Neuroprotective activity of the α7-nAChR positive allosteric modulator PNU-120596 on short term outcomes after traumatic brain injury. [PDF]

Exp Neurol
Winzer-Serhan UH, Ramakrishnan S, Li Y, Mada S, Reddy DS.   +4 more
europepmc   +1 more source

Kv3.1 activation suppresses provoked and spontaneous seizures in a mouse Dravet syndrome model

Epilepsia, EarlyView.
Abstract Objective γ‐Aminobutyric acidergic (GABAergic) parvalbumin‐positive (PV+) interneurons are critical for maintaining cortical inhibitory tone, with their dysfunction predictably leading to epilepsy. Rapid PV+ interneuron firing is essential for their normal function and is maintained in part by potassium voltage‐gated channels.
Sheryl Anne D. Vermudez, Mustafa Q. Hameed, Yongho Choe, Gabrielle E. McGinty, Amanda M. Liebhardt, Rui Lin, Benjamin Hui, Yini Liang, David J. Arce, Henry H. C. Lee, Mustafa Sahin, Alexander Rotenberg   +11 more
wiley   +1 more source

Phase 1 randomized trial of HS-10353, a novel GABA(A) positive allosteric modulator for treatment of major depressive disorder. [PDF]

BMC Med
Wang Z, Li M, Xu X, Zhang R, Lin H, Yang F, Qi J, Zhang H, Tao Y, Shen Q.   +9 more
europepmc   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Discovery of VU6052254: A Novel, Potent M₁ Positive Allosteric Modulator. [PDF]

ACS Chem Neurosci
Engers JL, Bungard JD, Presley CC, Zagol-Ikapitte I, Watson KJ, Chang S, O'Carroll C, Dey PM, Burstein ES, Dickerson JW, Thompson Gray A, Bubser M, Rook JM, Cho HP, Kramlinger VM, Boutaud O, Jones CK, Conn PJ, Engers DW, Lindsley CW.   +19 more
europepmc   +1 more source